Evaluate the status, opportunities and threats for pharmaceutical companies in Brazil, Russia, India and China now and in the future. This report includes market forecasts to 2010 plus three quarterly-updated market Outlook Reports on each country, keeping you up to date with developments for a full year.

This insightful report provides:
...
A comprehensive comparative overview of key drivers in the four markets
...
A detailed analysis of the health structure, funding, service and outlook for each market
...

5-Year forecasts to 2011 and market valuations for each markets

Quarterly updated reports of key developments in the market

These leading emerging and rapidly-growing economies represented a total market of 2.7 billion people and a combined GDP of US$5.2 trillion in 2006. But where do commercial opportunities exist for pharmaceutical companies now?

The combined GDP of the four BRIC countries in 2006 was estimated to be US$5,2 trillion. China accounts for US$2,532 billion or 48.1% of this. Combined BRIC GDP in 2006 stood at 19.5% of the combined GDP of the G6 countries; this compares with 13.4% in 2002. BRIC GDP accounted for 11% of world GDP in 2006, compared with 8.5% in 2002.

Putting things in perspective
The BRIC countries' total projected health expenditure in 2006 is estimated at US$266.2 billion. This is a large sum of money, but it is roughly equal to that spent by Germany alone each year. US total expenditure, at US$2.1 trillion, dwarfs this. China has by some way the largest health expenditure of the BRIC countries, at US$137 billion in 2006. This is a similar total amount to that spent by Canada. Average annual growth in expenditure is estimated at 11% for the 2006-11 period, taking the total to US$412.8 billion by 2011. Projected growth is fastest in India, at 15.3%, and slowest in Brazil, at 3.7%.

Opportunities do exist
There are, of course, wide regional differences in expenditure levels within the BRIC countries, far more so than in developed countries where health systems have evolved to provide a more uniform level of coverage. All four countries have a relatively wealthy urban population with a far greater spending power than their respective national average. In the case of China and India, these urban populations have grown rapidly, and number hundreds of millions. The challenge for these countries is to extend this level of wealth to the rest of the population, in order that better levels of healthcare become affordable.

A long haul
This is evolution not revolution. Short-term opportunities exist in meeting the health demands of the burgeoning middle classes, and future prospects bright where steady growth in BRIC markets will erode commercial differences with the established markets in North America, Japan and Europe.

Current and accurate decision support information is vital
Effective planning is vital, and impartial, thoroughly researched information is essential to fully appreciate the current status as a basis for future development. That is why Espicom Business Intelligence, the leading provider of market intelligence has published, in February 2007, the 340-page management report The Market for Pharmaceuticals in Brazil, Russia, India & China 2007. In addition to highly detailed chapters on each market, the report provides a thought-provoking and comparative examination of the BRIC economies, putting opportunities into their current and future context. BRAZIL

The Brazilian pharmaceutical market by value reached R$17.2 billion (US$7.9 billion) between January and September 2006, which represented a rise of 5.4% in local terms over R$16.3 billion (US$6.6 billion) in the same period in 2005. By September 2006, annual cumulative sales grew by 4.0% to R$23.1 billion or by 14.1% to US$10.5 billion, due to price adjustments and currency appreciation. Despite cost-containment measures, there is considerable potential for growth.

The generics sector continues to outperform the overall pharmacy sector. Price competition and local practices are diminishing foreign market penetration. The sector is expected to grow once generic production of contraceptives is legally allowed. Enforcement is expected in 2007 and production one year after its approval. RUSSIA

In 2006, the Russian pharmaceutical market was estimated at US$5.1 billion, equal to around US$36 per capita and comparable in size to Poland. In per capita terms, the market is similar to Ukraine. The market is split between imported products and cheap locally-produced generics, although imports are now taking a greater share of the market growth. Imports accounted for around 70% of the pharmaceutical market in 2004. The average price of an imported drug was US$3.15 in 2005, whereas the average price of a domestically-produced drug was US$0.58.

The reimbursement system is increasing the level of competition in the industry and is likely to result in foreign companies accounting for a larger share of the market. Domestic companies are under pressure to participate in the programme; not doing so will result in a reduction of their market share. It is expected that the pharmaceutical market will reach US$9.5 billion by 2011, or US$68 per capita. INDIA

With a population of over one billion, the pharmaceutical market in India has considerable potential. Espicom's market projections assume stable market growth of around 7.2% per year, putting the market at US$13.4 billion by 2011. It should be noted, however, that if calls for an end to drug price controls come to fruition, short-term market growth is likely to be much higher.

As India develops, the disease profile of the country is changing. Traditional infectious diseases such as smallpox have been eradicated and the number of cases of vaccine preventable conditions has also been greatly reduced. Along with life expectancy, however, the prevalence of western style diseases has been increasing. There are around 700,000 new cases of cancer each year and a total of around 2.5 million cases. Around two thirds of cases are in an advanced stage at the time of detection. The majority of these are smoking related cancers. CHINA

Pharmaceutical sales in China (excluding Hong Kong) were estimated at US$27.7 billion in 2005, an increase of around 8.5% over the previous year. The figure is distorted, however, by the presence of traditional Chinese medicines (TCMs). The TCM market is estimated at around US$6.9 billion. The size of the market for western-style pharmaceuticals, therefore, can be reckoned at around US$20.8 billion, equal to around US$16 per capita. This makes China one of the largest markets in the world, and second only to Japan in Asia. Per capita spending on pharmaceuticals remains among the lowest in the world, however, and is broadly comparable with Pakistan and India.

The Chinese pharmaceutical market has shown impressive growth in recent years, in tandem with the country's rapid economic expansion. The influx of foreign multinationals in recent years has offered continued investment, and production plants and R&D facilities are being expanded all the time. Improvements in regulatory practices are making the ability to sell imported products quicker and easier, while the lowering of tariffs on imported goods and an increase in transparency of legislation has made a notoriously hard-to-penetrate market a more attractive proposition for overseas companies.
DETAILED REPORT CONTENTS

COMPARATIVE OVERVIEW
This extensive section compares and contrasts the economic, health and medical operating environment in the 4 markets.

COUNTRY ANALYSIS

Key National Indicators
Economic, population, and health data forecast to 2011.

Healthcare system
Organisation & administration
Health expenditure
Expenditure by source of funding and type
Hospital services
Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures
Outpatient care
Medical personnel
Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists

...
The pharmaceutical market
Current market size
Unique 5-Year market projections to 2011
Market outlook & structure
Comment & rating of key areas

Accessing the medical market
Regulatory environment
Distribution guide and trade fair information
Domestic production

Contact details
For healthcare organisations and trade associations

QUARTERLY-UPDATED REPORTS INCLUDED!
Buyers of this report will receive, for each market, 4 quarterly reports covering:
Current market size
Unique 5-Year market projections to 2011
Market outlook & structure
Comment & rating
Imports and export data
Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, and funding.